Zimbabwe has declined a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' request for confidential biological samples.
This rejection became public following a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later stated that the US was requesting genetic material for scientific study and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further dialogue to find a deal suitable to all parties so the nation's critical HIV programme can continue.
Wider Context
This rejection follows a comparable case in Kenya, where a court suspended a related deal with the US following concerns were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and responsibility.
Based on reports, Sixteen nations in Africa have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our nation would supply the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens if a future pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a country contributes its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration could be structured in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it understood the government's concerns, but recommended that negotiations must proceed given that a large portion of the nation's HIV programmes relied on foreign aid.
"If specific concerns arise, such as those relating to data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group commented.
This impasse highlights the continuing tensions between accepting much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.